TrialBreast cancer research : BCR2025

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.

Kristina Fanucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.